She breastfed her little one for just over a year, and with all the new changes in her life, she was too busy to gain weight.Also read: Study links weight loss drug to rare eye conditionIn Europe, she ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE ...

Semaglutide has been shown to reduce the risk of complications in patients with chronic kidney disease, an indication for which it has been filed for approval, while tirzepatide has been shown to ...

and relentless deterioration of ß-cell function. After type 2 diabetes patients initially respond to diet and oral hypoglycemic agents, why do they usually relapse into hyperglycemia, despite ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a common liver disease that ...

Tirzepatide will be protected from inclusion in the negotiation list until 2030, as it was first approved in 2022, while semaglutide has been on the market since 2017. There was no word from Novo ...

A 2024 study suggests you may get better weight loss results with tirzepatide, the active ingredient in Zepbound and Mounjaro, than with semaglutide, the active ingredient in Ozempic and Wegovy.